Cassie Kline1,2, S John Liu3, Sai Duriseti4, Anuradha Banerjee5,6, Theodore Nicolaides6,7, Shannon Raber5, Nalin Gupta5,6, Daphne Haas-Kogan8, Steve Braunstein9, Sabine Mueller10,11,12. 1. Department of Pediatrics, University of California, San Francisco, CA, USA. cassie.kline@ucsf.edu. 2. Department of Neurology, University of California, San Francisco, CA, USA. cassie.kline@ucsf.edu. 3. School of Medicine, University of California, San Francisco, CA, USA. 4. Department of Radiation Oncology, Washington University in Saint Louis, St Louis, MO, USA. 5. Department of Pediatrics, University of California, San Francisco, CA, USA. 6. Department of Neurological Surgery, University of California, San Francisco, CA, USA. 7. Department of Pediatrics, New York University, New York, NY, USA. 8. Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA. 9. Department of Radiation Oncology, University of California, San Francisco, CA, USA. 10. Department of Pediatrics, University of California, San Francisco, CA, USA. sabine.mueller@ucsf.edu. 11. Department of Neurology, University of California, San Francisco, CA, USA. sabine.mueller@ucsf.edu. 12. Department of Neurological Surgery, University of California, San Francisco, CA, USA. sabine.mueller@ucsf.edu.
Abstract
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a rare, aggressive brain tumor with no known cure. Reirradiation (reRT) at recurrence can prolong survival. The impact of irradiation may be heightened when combined with PD-1 inhibition. We describe our experience using reRT, with or without PD-1 inhibition, in a cohort of patients with recurrent DIPG. METHODS: We performed a retrospective cohort analysis of children who received reRT with or without concomitant PD-1 inhibition for recurrent DIPG at a single institution between 2005 and 2016. We compared progression-free (PFS) and overall survival (OS) between those who received reRT alone or in combination with PD-1 inhibition. We then compared reRT to a cohort of patients who did not receive reRT. RESULTS: Thirty-one patients were included (8-reRT with nivolumab; 4-reRT alone; 19-no reRT). Patients who received reRT had prolonged OS compared to no reRT (22.9 months-reRT with nivolumab; 20.4 months-reRT alone; 8.3 months-no reRT; p < 0.0001). Patients who received reRT with nivolumab vs. reRT only had slightly prolonged OS from diagnosis and from reRT (22.9 vs. 20.4 months for time from diagnosis; 6.8 vs. 6.0 months for time from reRT). All patients receiving reRT with or without nivolumab tolerated the therapy without acute or late toxicity. CONCLUSIONS: Our experience demonstrates the tolerability of reRT with concurrent PD-1 inhibition for recurrent DIPG and suggests that combination therapy may offer survival benefit. Future prospective studies are needed to confirm the benefits of this combination therapy.
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a rare, aggressive brain tumor with no known cure. Reirradiation (reRT) at recurrence can prolong survival. The impact of irradiation may be heightened when combined with PD-1 inhibition. We describe our experience using reRT, with or without PD-1 inhibition, in a cohort of patients with recurrent DIPG. METHODS: We performed a retrospective cohort analysis of children who received reRT with or without concomitant PD-1 inhibition for recurrent DIPG at a single institution between 2005 and 2016. We compared progression-free (PFS) and overall survival (OS) between those who received reRT alone or in combination with PD-1 inhibition. We then compared reRT to a cohort of patients who did not receive reRT. RESULTS: Thirty-one patients were included (8-reRT with nivolumab; 4-reRT alone; 19-no reRT). Patients who received reRT had prolonged OS compared to no reRT (22.9 months-reRT with nivolumab; 20.4 months-reRT alone; 8.3 months-no reRT; p < 0.0001). Patients who received reRT with nivolumab vs. reRT only had slightly prolonged OS from diagnosis and from reRT (22.9 vs. 20.4 months for time from diagnosis; 6.8 vs. 6.0 months for time from reRT). All patients receiving reRT with or without nivolumab tolerated the therapy without acute or late toxicity. CONCLUSIONS: Our experience demonstrates the tolerability of reRT with concurrent PD-1 inhibition for recurrent DIPG and suggests that combination therapy may offer survival benefit. Future prospective studies are needed to confirm the benefits of this combination therapy.
Authors: Sophie E M Veldhuijzen van Zanten; Marc H A Jansen; Esther Sanchez Aliaga; Dannis G van Vuurden; W Peter Vandertop; Gertjan J L Kaspers Journal: Expert Rev Anticancer Ther Date: 2014-11-29 Impact factor: 4.512
Authors: Hiral P Fontanilla; Chelsea C Pinnix; Leena M Ketonen; Shiao Y Woo; Tribhawan S Vats; Michael E Rytting; Johannes E Wolff; Anita Mahajan Journal: Am J Clin Oncol Date: 2012-02 Impact factor: 2.339
Authors: Robbie G Majzner; Jason S Simon; Joseph F Grosso; Daniel Martinez; Bruce R Pawel; Mariarita Santi; Melinda S Merchant; Birgit Geoerger; Imene Hezam; Virginie Marty; Phillippe Vielh; Mads Daugaard; Poul H Sorensen; Crystal L Mackall; John M Maris Journal: Cancer Date: 2017-06-13 Impact factor: 6.860
Authors: Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen; David R Macdonald; Susan M Chang Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245
Authors: David A Reardon; Prafulla C Gokhale; Sarah R Klein; Keith L Ligon; Scott J Rodig; Shakti H Ramkissoon; Kristen L Jones; Amy Saur Conway; Xiaoyun Liao; Jun Zhou; Patrick Y Wen; Annick D Van Den Abbeele; F Stephen Hodi; Lei Qin; Nancy E Kohl; Arlene H Sharpe; Glenn Dranoff; Gordon J Freeman Journal: Cancer Immunol Res Date: 2015-11-06 Impact factor: 11.151
Authors: Anna Sophie Berghoff; Barbara Kiesel; Georg Widhalm; Orsolya Rajky; Gerda Ricken; Adelheid Wöhrer; Karin Dieckmann; Martin Filipits; Anita Brandstetter; Michael Weller; Sebastian Kurscheid; Monika E Hegi; Christoph C Zielinski; Christine Marosi; Johannes A Hainfellner; Matthias Preusser; Wolfgang Wick Journal: Neuro Oncol Date: 2014-10-29 Impact factor: 12.300
Authors: Lara Chavaz; Geert O Janssens; Stephanie Bolle; Henry Mandeville; Monica Ramos-Albiac; Karen Van Beek; Helen Benghiat; Bianca Hoeben; Andres Morales La Madrid; Clemens Seidel; Rolf-Dieter Kortmann; Darren Hargrave; Lorenza Gandola; Emilia Pecori; Dannis G van Vuurden; Veronica Biassoni; Maura Massimino; Christof M Kramm; Andre O von Bueren Journal: Front Oncol Date: 2022-06-22 Impact factor: 5.738
Authors: Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Hong In Yoon; Chan Woo Wee; Young Zoon Kim; Youngbeom Seo; Jung Ho Im; Yun Sik Dho; Kyung Hwan Kim; Je Beom Hong; Jae Sung Park; Seo Hee Choi; Min Sung Kim; Jangsup Moon; Kihwan Hwang; Ji Eun Park; Jin Mo Cho; Wan Soo Yoon; Se Hoon Kim; Young Il Kim; Ho Sung Kim; Kyoung Su Sung; Jin Ho Song; Min Ho Lee; Myung Hoon Han; Se Hoon Lee; Jong Hee Chang; Do Hoon Lim Journal: Brain Tumor Res Treat Date: 2021-04
Authors: Ryan J Duchatel; Abdul Mannan; Ameha S Woldu; Tom Hawtrey; Phoebe A Hindley; Alicia M Douglas; Evangeline R Jackson; Izac J Findlay; Zacary P Germon; Dilana Staudt; Padraic S Kearney; Nathan D Smith; Kate E Hindley; Jason E Cain; Nicolas André; Andres Morales La Madrid; Brett Nixon; Geoffry N De Iuliis; Javad Nazarian; Kathleen Irish; Frank Alvaro; David D Eisenstat; Alexander Beck; Nicholas A Vitanza; Sabine Mueller; Jonathan C Morris; Matthew D Dun Journal: Neurooncol Adv Date: 2021-11-19
Authors: S John Liu; Martina Malatesta; Brian V Lien; Parna Saha; Shivani S Thombare; Sung Jun Hong; Leslie Pedraza; Mark Koontz; Kyounghee Seo; Max A Horlbeck; Daniel He; Harjus S Birk; Miten Jain; Hugh E Olsen; Mark Akeson; Jonathan S Weissman; Michelle Monje; Nalin Gupta; David R Raleigh; Erik M Ullian; Daniel A Lim Journal: Genome Biol Date: 2020-03-31 Impact factor: 13.583